Star Chemist John Bower Takes Up Multimillion-Pound Chair at Bath to Boost Drug Discovery

The University of Bath has pulled off what its own chemistry leadership describes as a major academic coup, appointing Professor John Bower, one of the world’s leading synthetic and medicinal chemists, as the new Raymond Schinazi and Family Chair of Science. Bower took up the position in September, arriving from the University of Liverpool, where he had held the title of Regius Professor of Chemistry since 2020, one of the most prestigious academic appointments in British higher education. The move signals a deliberate and significant strengthening of Bath’s research excellence in organic and medicinal chemistry at a moment when the university is investing heavily in the translation of laboratory science into new medicines.

The chair itself is a relatively new institution, established in 2023 through a £2 million philanthropic gift from Professor Raymond F. Schinazi, a University of Bath alumnus whose career has become one of the most remarkable stories in modern antiviral research. Schinazi studied Chemistry at Bath, completing both his undergraduate degree and his doctorate there before building a distinguished career in academia and biotechnology in the United States. His pioneering work led to the development of antiviral medicines for HIV, hepatitis B and hepatitis C, and medicines developed through his research continue to benefit millions of patients worldwide. The chair bearing his name was created to attract scientists capable of following a similar trajectory, linking fundamental chemistry to therapies with global reach.

Schinazi himself welcomed the appointment, saying he was delighted that Bower would be the next holder of the chair. Throughout his career, he noted, he has seen how advances in chemistry can provide the foundation for breakthrough medicines that improve and save lives. In his view, Bower is an outstanding scientist who is exceptionally well placed to help advance Bath’s research strengths in medicinal chemistry and drug discovery. The endorsement carries particular weight coming from a donor whose own scientific legacy demonstrates exactly the kind of impact the endowment is designed to catalyse.

So what exactly does a synthetic and medicinal chemist of Bower’s standing do? At its core, synthetic organic chemistry is the science of building molecules, atom by atom and bond by bond, from simpler starting materials. When the target molecules are biologically active, the discipline becomes the engine room of drug discovery: nearly every small-molecule medicine on the pharmacy shelf, from antibiotics to antivirals to anticancer agents, exists because chemists worked out how to construct it efficiently, selectively and, increasingly, sustainably. The craft demands mastery of catalysis, the use of substances that accelerate and steer chemical reactions, and of molecular design, the rational shaping of a molecule’s three-dimensional architecture so that it interacts precisely with biological targets such as enzymes or receptors.

Bower’s research programme sits squarely at this intersection. His work combines synthetic organic chemistry, catalysis and molecular design to develop new sustainable processes for the synthesis of biologically active molecules. That emphasis on sustainability reflects a broader shift across the pharmaceutical and fine-chemical industries, where traditional synthesis routes can be lengthy, wasteful and reliant on hazardous reagents. Modern catalytic methods, by contrast, can shorten synthetic sequences, reduce solvent use and waste, and open access to molecular structures that would otherwise be impractical to make. For medicinal chemistry, the practical consequence is enormous: when a promising drug candidate can be assembled in fewer steps and higher yield, researchers can prepare more analogues more quickly, accelerating the optimisation cycles that turn a laboratory hit into a developable medicine.

Bower’s path to Bath traces a classic route through some of the strongest chemistry departments in the world. He obtained his MSci degree in Chemistry and his PhD from the University of Bristol, before pursuing postdoctoral positions at the University of Texas at Austin and the University of Oxford, two environments renowned for pushing the frontiers of synthetic methodology. He then returned to Bristol to establish his independent research group, building the reputation that led to his move to Liverpool ten years later, in 2020, where he was appointed Regius Professor of Chemistry. The Regius professorships are royal appointments of great historical distinction, and holding one marks a chemist out as being at the very top of the discipline in the United Kingdom.

His arrival in Bath is timed to complement and strengthen the university’s existing capabilities in organic chemistry, medicinal chemistry and biochemistry, including the recent launch of the university’s Centre for Drug Discovery. That centre represents Bath’s ambition to build an integrated pipeline in which fundamental molecular science, biological evaluation and translational development operate in close proximity. Appointing a chair of Bower’s calibre to anchor the synthetic chemistry side of that pipeline is a strategic statement: the university intends to compete internationally not only in understanding biology but in designing and making the molecules that can modulate it. In announcing the appointment, the university described it as a significant strengthening of its growing research excellence in organic and medicinal chemistry.

Professor Matthew Jones, Head of Bath’s Department of Chemistry, was unequivocal about the significance of the hire. John, he said, is an extremely accomplished chemist, and his appointment is a major academic coup. His expertise in synthetic and medicinal chemistry, Jones added, will significantly enhance the department’s research capabilities and strengthen its growing portfolio in this area. Jones also paid tribute to the donor behind the chair, saying the department is incredibly grateful to Professor Raymond Schinazi for his extraordinary support, which has enabled Bath to attract a scientist of John’s calibre and further strengthen the university’s position as an international centre for chemistry, medicinal science and drug discovery.

For his part, Bower expressed enthusiasm about the move and about the environment he is joining. He said he is thrilled to be joining the University of Bath as the Raymond Schinazi and Family Chair of Science, noting that Bath has an outstanding reputation for world-class chemistry and a strong commitment to translating fundamental research into real-world impact. He added that he looks forward to working with colleagues across the university to develop his research in ways that can ultimately support the translation of research to application. That translation-focused language echoes the founding purpose of the chair itself, and it suggests that Bower’s laboratory will be expected to operate not merely as a generator of elegant synthetic methods but as a source of chemistry that can flow directly into drug discovery programmes.

The broader significance of the appointment lies in what it says about the state of British chemistry and the philanthropy that increasingly supports it. Endowed chairs funded by private gifts remain comparatively rare in UK science, and one established by an alumnus whose own chemistry produced medicines used by millions of patients gives the position a symbolic resonance few appointments can match. It links a department’s future to a demonstrated proof of concept: rigorous synthetic chemistry, pursued with ambition and translated with determination, can change the course of global public health. As Bower builds his group at Bath, the expectation, set by both the donor and the university, is that the molecules his team learns to make will not simply advance the art of synthesis but move steadily closer to the clinic, continuing a tradition that began with the man whose name now heads the chair.

Subject of Research: Appointment of synthetic and medicinal chemist Professor John Bower as the Raymond Schinazi and Family Chair of Science at the University of Bath

Article Title: Top synthetic and medicinal chemist joins Bath as new Schinazi and Family Chair of Science

Article References: Top synthetic and medicinal chemist joins Bath as new Schinazi and Family Chair of Science. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: John Bower, University of Bath, Raymond Schinazi, synthetic chemistry, medicinal chemistry, drug discovery, catalysis, organic chemistry, antiviral drugs, philanthropy, Regius Professor, Centre for Drug Discovery